HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Carumonam versus ceftazidime for urinary tract infections.

AbstractCarumonam is a new monobactam antibiotic with potent activity against gram-negative aerobes. To study the efficacy and safety of carumonam for treatment of complicated and uncomplicated urinary tract infections, 54 patients were randomized to therapy with either carumonam or ceftazidime. Of 42 patients who could be evaluated, 82% of the carumonam-treated patients and 80% of the ceftazidime-treated patients were cured clinically. At 5 to 9 days posttherapy, microbiologic criteria indicated that 13 carumonam-treated patients (48%) and 8 ceftazidime-treated patients (53%) were cured. Patients with indwelling bladder catheters at the end of therapy had a markedly worse microbiologic outcome than those without catheters. Enterococcus sp. reinfection was common in both groups. Possible adverse clinical and laboratory reactions occurred in six carumonam-treated patients (21%) and four ceftazidime-treated patients (27%). Most reactions occurred at the end of therapy and resolved with discontinuation of the study drug. In this small study, carumonam appeared as safe and as effective as ceftazidime for the treatment of complicated and uncomplicated urinary tract infections.
AuthorsH Edelstein, S Oster, K Cassano, R McCabe (Affiliation: Section of Infectious Diseases, Veterans Administration Medical Center, Martinez, California 94553.)
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 32 Issue 7 Pg. 1031-3 (Jul 1988) ISSN: 0066-4804 [Print] UNITED STATES
PMID3056245 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Aztreonam
  • Ceftazidime
  • carumonam
Topics
  • Adult
  • Anti-Bacterial Agents (therapeutic use)
  • Aztreonam (analogs & derivatives)
  • Bacterial Infections (drug therapy)
  • Ceftazidime (therapeutic use)
  • Drug Tolerance
  • Female
  • Humans
  • Male
  • Urinary Tract Infections (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD